{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:36:53Z","timestamp":1787020613503,"version":"build-2736575974"},"reference-count":162,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Fondazione Italiana Linfomi, FIL","award":["PGREd. 2019 to F.M.Q., MANTLE-FIRST BIO study"],"award-info":[{"award-number":["PGREd. 2019 to F.M.Q., MANTLE-FIRST BIO study"]}]},{"name":"European Union, MUR, MSAL","award":["PNRR-TR1-2023-12378287 to C.V."],"award-info":[{"award-number":["PNRR-TR1-2023-12378287 to C.V."]}]},{"name":"European Union, MUR, MSAL","award":["PNRR-PNC\u2010E3\u20102022\u201023683266 PNC\u2010HLS\u2010DA-INNOVA to M.T.S."],"award-info":[{"award-number":["PNRR-PNC\u2010E3\u20102022\u201023683266 PNC\u2010HLS\u2010DA-INNOVA to M.T.S."]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Commun Signal"],"DOI":"10.1186\/s12964-025-02468-6","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T15:23:56Z","timestamp":1762874636000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["B-cell receptor signaling and microenvironment crosstalk in mantle cell lymphoma"],"prefix":"10.1186","volume":"23","author":[{"given":"Francesca Maria","family":"Quaglia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Gambino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilisa","family":"Galasso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Carmela","family":"Vegliante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Visco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Teresa","family":"Scupoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,11]]},"reference":[{"key":"2468_CR1","doi-asserted-by":"publisher","unstructured":"Dreyling M, Campo E, Hermine O, Jerkeman M, Le Gouill S, Rule S, et al. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(Supplement 4):iv62\u201371. Available from: https:\/\/doi.org\/10.1093\/annonc\/mdx223","DOI":"10.1093\/annonc\/mdx223"},{"key":"2468_CR2","doi-asserted-by":"crossref","unstructured":"Jain P, Wang ML. Mantle cell lymphoma in 2022\u2014A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments. Am J Hematol. 2022 [cited 2022 Aug 1];97(5):638\u201356. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/35266562\/","DOI":"10.1002\/ajh.26523"},{"issue":"3","key":"2468_CR3","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1002\/cncr.11096","volume":"97","author":"JE Romaguera","year":"2003","unstructured":"Romaguera JE, Medeiros LJ, Hagemeister FB, Fayad LE, Rodriguez MA, Pro B, et al. Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma. Cancer. 2003;97(3):586\u201391. https:\/\/doi.org\/10.1002\/cncr.11096.","journal-title":"Cancer"},{"key":"2468_CR4","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.hoc.2020.05.002","volume":"34","author":"A Navarro","year":"2020","unstructured":"Navarro A, Be\u00e0 S, Jares P, Campo E, Elsevier. Molecular pathogenesis of mantle cell lymphoma. Hematol Oncol Clin North Am. 2020;34:795\u2013807.","journal-title":"Hematol Oncol Clin North Am"},{"key":"2468_CR5","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IB de O, Berti E, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022 [cited 2025 Jun 6];36(7):1720\u201348. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/35732829\/"},{"key":"2468_CR6","unstructured":"Campo E, Jaffe ES, Cook JR, Quintanilla-Martinez L, Swerdlow SH, Anderson KC, et al. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood. 2022 [cited 2023 Mar 20];140(11):1229\u201353. Available from: https:\/\/ashpublications.org\/blood\/article\/140\/11\/1229\/485458\/The-International-Consensus-Classification-of"},{"key":"2468_CR7","doi-asserted-by":"crossref","unstructured":"Hoster E, Rosenwald A, Berger F, Bernd HW, Hartmann S, Loddenkemper C, et al. Prognostic value of Ki-67 index, cytology, and growth pattern in mantle-cell lymphoma: Results from randomized trials of the european mantle cell lymphoma network. In: Journal of Clinical Oncology. American Society of Clinical Oncology. 2016;1386\u201394. Available from: https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2015.63.8387?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed.","DOI":"10.1200\/JCO.2015.63.8387"},{"key":"2468_CR8","doi-asserted-by":"crossref","unstructured":"Silkenstedt E, Dreyling M. Mantle cell lymphoma\u2014Update on molecular biology, prognostication and treatment approaches. Hematol Oncol. 2023 [cited 2025 Jun 6];41(S1):36\u201342. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/37294961\/","DOI":"10.1002\/hon.3149"},{"key":"2468_CR9","doi-asserted-by":"crossref","unstructured":"Visco C, Di Rocco A, Evangelista A, Quaglia FM, Tisi MC, Morello L, et al. Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study. Leukemia. 2021 [cited 2023 Apr 12];35(3):787\u201395. Available from: https:\/\/www.nature.com\/articles\/s41375-020-01013-3","DOI":"10.1038\/s41375-020-01013-3"},{"key":"2468_CR10","doi-asserted-by":"crossref","unstructured":"Quaglia FM, Visco C. Mantle cell lymphoma patients in first relapse: We pretty much know what to do. Vol. 12, Oncotarget. Impact Journals, LLC; 2021 [cited 2023 Apr 12]. p. 1724\u20136. Available from: \/pmc\/articles\/PMC8378770\/","DOI":"10.18632\/oncotarget.27980"},{"key":"2468_CR11","doi-asserted-by":"crossref","unstructured":"Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, et al. Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma. New Engl J Med. 2013 [cited 2022 Oct 31];369(6):507\u201316. Available from: \/pmc\/articles\/PMC4513941\/","DOI":"10.1056\/NEJMoa1306220"},{"key":"2468_CR12","doi-asserted-by":"crossref","unstructured":"Wang Y, Zhang LL, Champlin RE, Wang ML. Targeting Bruton\u2019s Tyrosine Kinase With Ibrutinib in B-Cell Malignancies. Clin Pharmacol Ther. 2015 [cited 2024 Apr 3];97(5):455\u201368. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/cpt.85","DOI":"10.1002\/cpt.85"},{"key":"2468_CR13","doi-asserted-by":"crossref","unstructured":"Hershkovitz-Rokah O, Pulver D, Lenz G, Shpilberg O. Ibrutinib resistance in mantle cell lymphoma: clinical, molecular and treatment aspects. Br J Haematol. 2018 [cited 2025 Jun 6];181(3):306\u201319. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/29359797\/","DOI":"10.1111\/bjh.15108"},{"key":"2468_CR14","doi-asserted-by":"crossref","unstructured":"Burger JA. BTK Inhibitors: present and future. Cancer J. 2019 [cited 2025 Jun 6];25(6):386. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC7083517\/","DOI":"10.1097\/PPO.0000000000000412"},{"key":"2468_CR15","doi-asserted-by":"crossref","unstructured":"Jares P, Colomer D, Campo E. Molecular pathogenesis of mantle cell lymphoma. J Clin Investigat. 2012;122(10):3416\u201323. Available from: http:\/\/www.jci.org\/articles\/view\/61272","DOI":"10.1172\/JCI61272"},{"key":"2468_CR16","doi-asserted-by":"crossref","unstructured":"Wlodarska I, Dierickx D, Vanhentenrijk V, Van Roosbroeck K, Posp\u00ed\u0161ilov\u00e1 H, Minnei F, et al. Translocations targeting CCND2, CCND3, and MYCN do occur in t(11;14)-negative mantle cell lymphomas. Blood. 2008 [cited 2025 Jun 6];111(12):5683\u201390. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/18391076\/","DOI":"10.1182\/blood-2007-10-118794"},{"key":"2468_CR17","doi-asserted-by":"crossref","unstructured":"Queir\u00f3s AC, Beekman R, Vilarrasa-Blasi R, Duran-Ferrer M, Clot G, Merkel A, et al. Decoding the DNA methylome of mantle cell lymphoma in the light of the entire B cell lineage. Cancer Cell. 2016 [cited 2025 Jun 6];30(5):806. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC5805090\/","DOI":"10.1016\/j.ccell.2016.09.014"},{"issue":"20","key":"2468_CR18","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1182\/blood-2018-02-832535","volume":"131","author":"PY Kuo","year":"2018","unstructured":"Kuo PY, Jatiani SS, Rahman AH, Edwards D, Jiang Z, Ahr K, et al. Sox11 augments bcr signaling to drive mcl-like tumor development. Blood. 2018;131(20):2247\u201355. https:\/\/doi.org\/10.1182\/blood-2018-02-832535.","journal-title":"Blood"},{"key":"2468_CR19","doi-asserted-by":"crossref","unstructured":"Palomero J, Vegliante MC, Eguileor A, Rodr ML, Balsas P, Mart D, et al. SOX11 defines two different subtypes of mantle cell lymphoma through transcriptional regulation of BCL6. 2016; Available from: http:\/\/www.nature.com\/leu","DOI":"10.1038\/leu.2015.355"},{"key":"2468_CR20","doi-asserted-by":"crossref","unstructured":"Cobaleda C, Jochum W, Busslinger M. Conversion of mature B cells into T cells by dedifferentiation to uncommitted progenitors. Nature. 2007 [cited 2025 Jun 6];449(7161):473\u20137. Available from: https:\/\/www.nature.com\/articles\/nature06159","DOI":"10.1038\/nature06159"},{"key":"2468_CR21","doi-asserted-by":"publisher","unstructured":"Nera KP, Lassila O. Pax5 \u2013 a Critical Inhibitor of Plasma Cell Fate. Scand J Immunol. 2006 [cited 2025 Jun 6];64(3):190\u20139. Available from: https:\/\/doi.org\/10.1111\/j.1365-3083.2006.01809.x","DOI":"10.1111\/j.1365-3083.2006.01809.x"},{"key":"2468_CR22","doi-asserted-by":"crossref","unstructured":"Vegliante MC, Palomero J, P\u00e9rez-Gal\u00e1n P, Rou\u00e9 G, Castellano G, Navarro A, et al. SOX11 regulates PAX5 expression and blocks terminal B-cell differentiation in aggressive mantle cell lymphoma. Blood. 2013 [cited 2022 Aug 8];121(12):2175\u201385. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/23321250\/","DOI":"10.1182\/blood-2012-06-438937"},{"key":"2468_CR23","doi-asserted-by":"crossref","unstructured":"Be\u00e0 S, Vald\u00e9s-Mas R, Navarro A, Salaverria I, Mart\u00edn-Garcia D, Jares P, et al. Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. Proc Natl Acad Sci U S A. 2013 [cited 2022 Aug 8];110(45):18250\u20135. Available from: \/pmc\/articles\/PMC3831489\/","DOI":"10.1073\/pnas.1314608110"},{"key":"2468_CR24","doi-asserted-by":"crossref","unstructured":"Greiner TC, Dasgupta C, Ho V V., Weisenburger DD, Smith LM, Lynch JC, et al. Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma. Proc Natl Acad Sci U S A [Internet]. 2006 [cited 2022 Aug 9];103(7):2352\u20137. Available from: https:\/\/www.pnas.org\/doi\/abs\/10.1073\/pnas.0510441103","DOI":"10.1073\/pnas.0510441103"},{"issue":"13","key":"2468_CR25","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1182\/bloodadvances.2019001350","volume":"4","author":"HA Hill","year":"2020","unstructured":"Hill HA, Qi X, Jain P, Nomie K, Wang Y, Zhou S, et al. Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis. Blood Adv. 2020;4(13):2927\u201338. https:\/\/doi.org\/10.1182\/bloodadvances.2019001350.","journal-title":"Blood Adv"},{"key":"2468_CR26","doi-asserted-by":"crossref","unstructured":"Sethi S, Epstein-Peterson Z, Kumar A, Ho C. Current Knowledge in Genetics, Molecular Diagnostic Tools, and Treatments for Mantle Cell Lymphomas. Front Oncol. 2021 [cited 2025 Jun 6];11:739441. Available from: www.frontiersin.org","DOI":"10.3389\/fonc.2021.739441"},{"key":"2468_CR27","doi-asserted-by":"crossref","unstructured":"Navarro A, Clot G, Royo C, Jares P, Hadzidimitriou A, Agathangelidis A, et al. Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features. Cancer Res. 2012 [cited 2022 Aug 8];72(20):5307\u201316. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/22915760\/","DOI":"10.1158\/0008-5472.CAN-12-1615"},{"issue":"5","key":"2468_CR28","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1182\/blood-2015-02-628792","volume":"126","author":"MH Delfau-Larue","year":"2015","unstructured":"Delfau-Larue MH, Klapper W, Berger F, et al. High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma. Blood. 2015;126(5):604\u201311. https:\/\/doi.org\/10.1182\/blood-2015-02-628792.","journal-title":"Blood"},{"issue":"July","key":"2468_CR29","first-page":"1","volume":"9","author":"Q Zhang","year":"2019","unstructured":"Zhang Q, Wang HY, Liu X, Roth MH, Shestov AA, Lee SC, et al. Dynamic Changes in Gene Mutational Landscape With Preservation of Core Mutations in Mantle Cell Lymphoma Cells. Front Oncol. 2019;9(July):1\u20139.","journal-title":"Front Oncol"},{"key":"2468_CR30","doi-asserted-by":"crossref","unstructured":"Zhang J, Jima D, Moffitt AB, Liu Q, Czader M, Hsi ED, et al. The genomic landscape of mantle cell lymphoma is related to the epigenetically determined chromatin state of normal B cells. Blood. 2014 [cited 2025 Jun 6];123(19):2988\u201396. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/24682267\/","DOI":"10.1182\/blood-2013-07-517177"},{"issue":"1","key":"2468_CR31","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41591-018-0243-z","volume":"25","author":"R Agarwal","year":"2019","unstructured":"Agarwal R, Chan YC, Tam CS, Hunter T, Vassiliadis D, Teh CE, et al. Dynamic molecular monitoring reveals that SWI\u2013SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma. Nat Med. 2019;25(1):119\u201329. https:\/\/doi.org\/10.1038\/s41591-018-0243-z.","journal-title":"Nat Med"},{"issue":"16","key":"2468_CR32","doi-asserted-by":"publisher","first-page":"3161","DOI":"10.1182\/blood-2013-01-478834","volume":"121","author":"B Meissner","year":"2013","unstructured":"Meissner B, Kridel R, Lim RS, Rogic S, Tse K, Scott DW, et al. The E3 ubiquitin ligase UBR5 is recurrently mutated in mantle cell lymphoma. Blood. 2013;121(16):3161\u20134. https:\/\/doi.org\/10.1182\/blood-2013-01-478834.","journal-title":"Blood"},{"key":"2468_CR33","doi-asserted-by":"crossref","unstructured":"Nadeu F, Martin-Garcia D, Clot G, D\u00edaz-Navarro A, Duran-Ferrer M, Navarro A, et al. Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes. Blood. 2020 [cited 2023 Mar 24];136(12):1419\u201332. Available from: https:\/\/ashpublications.org\/blood\/article\/136\/12\/1419\/461130\/Genomic-and-epigenomic-insights-into-the-origin","DOI":"10.1182\/blood.2020005289"},{"issue":"5","key":"2468_CR34","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1182\/blood.2019002385","volume":"136","author":"P Pararajalingam","year":"2020","unstructured":"Pararajalingam P, Coyle KM, Arthur SE, Thomas N, Alcaide M, Meissner B, et al. Coding and noncoding drivers of mantle cell lymphoma identified through exome and genome sequencing. Blood. 2020;136(5):572\u201384. https:\/\/doi.org\/10.1182\/blood.2019002385.","journal-title":"Blood"},{"key":"2468_CR35","doi-asserted-by":"crossref","unstructured":"Wu C, Miranda NF de, Chen L, Wasik AM, Mansouri L, Jurczak W, et al. Genetic heterogeneity in primary and relapsed mantle cell lymphomas: Impact of recurrent CARD11 mutations. Oncotarget. 2016 [cited 2022 Sep 15];7(25):38180\u201390. Available from: https:\/\/www.oncotarget.com\/article\/9500\/text\/","DOI":"10.18632\/oncotarget.9500"},{"key":"2468_CR36","doi-asserted-by":"crossref","unstructured":"Rahal R, Frick M, Romero R, Korn JM, Kridel R, Chan FC, et al. Pharmacological and genomic profiling identifies NF-\u03baB-targeted treatment strategies for mantle cell lymphoma. Nat Med. 2014 [cited 2022 Sep 15];20(1):87\u201392. Available from: https:\/\/www.nature.com\/articles\/nm.3435","DOI":"10.1038\/nm.3435"},{"key":"2468_CR37","doi-asserted-by":"crossref","unstructured":"Kridel R, Meissner B, Rogic S, Boyle M, Telenius A, Woolcock B, et al. Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma. Blood. 2012 [cited 2022 Aug 9];119(9):1963\u201371. Available from: https:\/\/ashpublications.org\/blood\/article\/119\/9\/1963\/30249\/Whole-transcriptome-sequencing-reveals-recurrent","DOI":"10.1182\/blood-2011-11-391474"},{"key":"2468_CR38","doi-asserted-by":"crossref","unstructured":"Chiron D, Di Liberto M, Martin P, Huang X, Sharman J, Blecua P, et al. Cell-cycle reprogramming for Pi3K inhibition overrides a relapse-specific C481s BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma. Cancer Discov. 2014 [cited 2023 Feb 15];4(9):1022\u201335. Available from: https:\/\/aacrjournals.org\/cancerdiscovery\/article\/4\/9\/1022\/6452\/Cell-Cycle-Reprogramming-for-PI3K-Inhibition","DOI":"10.1158\/2159-8290.CD-14-0098"},{"key":"2468_CR39","doi-asserted-by":"crossref","unstructured":"Martin P, Maddocks K, Leonard JP, Ruan J, Goy A, Wagner-Johnston N, et al. Postibrutinib outcomes in patients with mantle cell lymphoma. In: Blood. 2016. p. 1559\u201363. Available from: http:\/\/ashpublications.org\/blood\/article-pdf\/127\/12\/1559\/1392437\/1559.pdf","DOI":"10.1182\/blood-2015-10-673145"},{"key":"2468_CR40","doi-asserted-by":"crossref","unstructured":"Stilgenbauer S, Nickolenko J, Wilhelm J, Wolf S, Weitz S, D\u00f6hner K, et al. Expressed sequences as candidates for a novel tumor suppressor gene at band 13q14 in B-cell chronic lymphocytic leukemia and mantle cell lymphoma. Oncogene. 1998 [cited 2025 Jun 6];16(14):1891\u20137. Available from: https:\/\/www.nature.com\/articles\/1201764","DOI":"10.1038\/sj.onc.1201764"},{"key":"2468_CR41","doi-asserted-by":"crossref","unstructured":"Puente XS, Jares P, Campo E. Chronic lymphocytic leukemia and mantle cell lymphoma: crossroads of genetic and microenvironment interactions. Blood. 2018;131(21):2283\u201396. Available from: https:\/\/ashpublications.org\/blood\/article\/131\/21\/2283\/37126\/Chronic-lymphocytic-leukemia-and-mantle-cell","DOI":"10.1182\/blood-2017-10-764373"},{"key":"2468_CR42","doi-asserted-by":"crossref","unstructured":"Melchers F. Checkpoints that control B cell development. J Clin Invest. 2015 [cited 2025 Jun 6];125(6):2203. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC4497745\/","DOI":"10.1172\/JCI78083"},{"key":"2468_CR43","doi-asserted-by":"crossref","unstructured":"Dal Porto JM, Burke K, Cambier JC. Regulation of BCR signal transduction in B-1 cells requires the expression of the Src family kinase Lck. Immunity. 2004 [cited 2024 Jan 15];21(3):443\u201353. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/15357954\/","DOI":"10.1016\/j.immuni.2004.07.018"},{"key":"2468_CR44","doi-asserted-by":"crossref","unstructured":"Dai B, Grau M, Juilland M, Klener P, H\u00f6ring E, Molinsky J, et al. B-cell receptor\u2013driven MALT1 activity regulates MYC signaling in mantle cell lymphoma. Blood. 2017;129(3):333\u201346. Available from: http:\/\/ashpublications.org\/blood\/article-pdf\/129\/3\/333\/1401618\/blood718775.pdf","DOI":"10.1182\/blood-2016-05-718775"},{"key":"2468_CR45","doi-asserted-by":"crossref","unstructured":"Shaffer AL, Young RM, Staudt LM. Pathogenesis of Human B Cell Lymphomas. Annu Rev Immunol. 2012 [cited 2025 Jun 6];30:565. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC7478144\/","DOI":"10.1146\/annurev-immunol-020711-075027"},{"key":"2468_CR46","doi-asserted-by":"crossref","unstructured":"Okkenhaug K. Signalling by the phosphoinositide 3-kinase family in immune cells. Annu Rev Immunol. 2013 [cited 2025 Jun 6];31:675. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC4516760\/","DOI":"10.1146\/annurev-immunol-032712-095946"},{"key":"2468_CR47","doi-asserted-by":"crossref","unstructured":"Okkenhaug K, Vanhaesebroeck B. PI3K in lymphocyte development, differentiation and activation. Nat Rev Immunol. 2003 [cited 2025 Jun 6];3(4):317\u201330. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/12669022\/","DOI":"10.1038\/nri1056"},{"issue":"6","key":"2468_CR48","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.cell.2004.05.014","volume":"117","author":"M Kraus","year":"2004","unstructured":"Kraus M, Alimzhanov MB, Rajewsky N, Rajewsky K. Survival of resting mature B lymphocytes depends on BCR signaling via the Ig\u03b1\/\u03b2 heterodimer. Cell. 2004;117(6):787\u2013800.","journal-title":"Cell"},{"issue":"3","key":"2468_CR49","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.cell.2009.08.041","volume":"139","author":"L Srinivasan","year":"2009","unstructured":"Srinivasan L, Sasaki Y, Calado DP, Zhang B, Paik JH, DePinho RA, et al. PI3 kinase signals BCR-dependent mature B cell survival. Cell. 2009;139(3):573\u201386.","journal-title":"Cell"},{"issue":"18","key":"2468_CR50","doi-asserted-by":"publisher","first-page":"5065","DOI":"10.1073\/pnas.1604529113","volume":"113","author":"E Derudder","year":"2016","unstructured":"Derudder E, Herzog S, Labi V, Yasuda T, K\u00f6chert K, Janz M, et al. Canonical NF-\u03bab signaling is uniquely required for the long-term persistence of functional mature B cells. Proc Natl Acad Sci U S A. 2016;113(18):5065\u201370. https:\/\/doi.org\/10.1073\/pnas.1604529113.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2468_CR51","doi-asserted-by":"crossref","unstructured":"Scupoli MT, Pizzolo G. Signaling pathways activated by the B-cell receptor in chronic lymphocytic leukemia. Vol. 5, Expert Review of Hematology. Taylor & Francis; 2012 [cited 2023 Jan 30]. p. 341\u20138. Available from: https:\/\/www.tandfonline.com\/doi\/abs\/10.1586\/ehm.12.21","DOI":"10.1586\/ehm.12.21"},{"issue":"6","key":"2468_CR52","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1182\/blood.V94.6.1848","volume":"94","author":"TJ Hamblin","year":"1999","unstructured":"Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig VH genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94(6):1848\u201354. https:\/\/doi.org\/10.1182\/blood.V94.6.1848.","journal-title":"Blood"},{"key":"2468_CR53","doi-asserted-by":"crossref","unstructured":"Packham G, Krysov S, Allen A, Savelyeva N, Steele AJ, Forconi F, et al. The outcome of B-cell receptor signaling in chronic lymphocytic leukemia: Proliferation or anergy. Vol. 99, Haematologica. Ferrata Storti Foundation; 2014 [cited 2021 Apr 14]. p. 1138\u201348. Available from: https:\/\/haematologica.org\/article\/view\/7077","DOI":"10.3324\/haematol.2013.098384"},{"key":"2468_CR54","doi-asserted-by":"crossref","unstructured":"Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL, et al. Ig V Gene Mutation Status and CD38 Expression As Novel Prognostic Indicators in Chronic Lymphocytic Leukemia. Blood. 1999 [cited 2025 Jun 6];94(6):1840\u20137. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0006497120488901?via%3Dihub","DOI":"10.1182\/blood.V94.6.1840.418k06_1840_1847"},{"issue":"12","key":"2468_CR55","doi-asserted-by":"publisher","first-page":"4389","DOI":"10.1182\/blood-2003-12-4312","volume":"103","author":"FK Stevenson","year":"2004","unstructured":"Stevenson FK, Caligaris-Cappio F. Chronic lymphocytic leukemia: revelations from the B-cell receptor. Blood. 2004;103(12):4389\u201395. https:\/\/doi.org\/10.1182\/blood-2003-12-4312.","journal-title":"Blood"},{"key":"2468_CR56","doi-asserted-by":"crossref","unstructured":"Agathangelidis A, Psomopoulos F, Stamatopoulos K. Stereotyped B cell receptor immunoglobulins in B cell lymphomas. Method Mol Biology. 2019 [cited 2025 Jun 6];1956:139\u201355. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/30779034\/","DOI":"10.1007\/978-1-4939-9151-8_7"},{"key":"2468_CR57","doi-asserted-by":"crossref","unstructured":"Caligaris-Cappio F, Ghia P. Novel Insights in Chronic Lymphocytic Leukemia: Are We Getting Closer to Understanding the Pathogenesis of the Disease? J Clin Oncol. 2008 [cited 2025 Jun 6];26(27):4497\u2013503. Available from: https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2007.15.4393","DOI":"10.1200\/JCO.2007.15.4393"},{"key":"2468_CR58","doi-asserted-by":"crossref","unstructured":"Thurner L, Hartmann S, Neumann F, Hoth M, Stilgenbauer S, K\u00fcppers R, et al. Role of Specific B-Cell Receptor Antigens in Lymphomagenesis. Front Oncol [Internet]. 2020 [cited 2025 Jan 23];10:604685. Available from: www.frontiersin.org","DOI":"10.3389\/fonc.2020.604685"},{"key":"2468_CR59","doi-asserted-by":"crossref","unstructured":"Thurner L, Hartmann S, Bewarder M, Fadle N, Regitz E, Schormann C, et al. Identification of the atypically modified autoantigen Ars2 as the target of B-cell receptors from activated B-cell-type diffuse large B-cell lymphoma. Haematologica. 2021 [cited 2025 Jan 23];106(8):2224\u201332. Available from: https:\/\/haematologica.org\/article\/view\/9806","DOI":"10.3324\/haematol.2019.241653"},{"key":"2468_CR60","doi-asserted-by":"crossref","unstructured":"Stamatopoulos K, Agathangelidis A, Rosenquist R, Ghia P. Antigen receptor stereotypy in chronic lymphocytic leukemia. Leukemia 2017 31:2. 2016 [cited 2025 Jun 6];31(2):282\u201391. Available from: https:\/\/www.nature.com\/articles\/leu2016322","DOI":"10.1038\/leu.2016.322"},{"key":"2468_CR61","doi-asserted-by":"crossref","unstructured":"Hadzidimitriou A, Agathangelidis A, Darzentas N, Murray F, Delfau-Larue MH, Pedersen LB, et al. Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases. Blood. 2011 [cited 2022 Aug 8];118(11):3088\u201395. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/21791422\/","DOI":"10.1182\/blood-2011-03-343434"},{"key":"2468_CR62","doi-asserted-by":"crossref","unstructured":"Krysov S, Dias S, Paterson A, Mockridge CI, Potter KN, Smith KA, et al. Surface IgM stimulation induces MEK1\/2-dependent MYC expression in chronic lymphocytic leukemia cells. Blood. 2012 [cited 2025 Jun 6];119(1):170\u20139. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/22086413\/","DOI":"10.1182\/blood-2011-07-370403"},{"issue":"2","key":"2468_CR63","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1182\/blood-2011-12-397158","volume":"120","author":"C Le Roy","year":"2012","unstructured":"Le Roy C, Deglesne PA, Chevallier N, Beitar T, Eclache V, Quettier M, et al. The degree of BCR and NFAT activation predicts clinical outcomes in chronic lymphocytic leukemia. Blood. 2012;120(2):356\u201365. https:\/\/doi.org\/10.1182\/blood-2011-12-397158.","journal-title":"Blood"},{"issue":"4","key":"2468_CR64","doi-asserted-by":"publisher","first-page":"626","DOI":"10.3324\/haematol.2012.071910","volume":"98","author":"A Cesano","year":"2013","unstructured":"Cesano A, Perbellini O, Evensen E, Chu CC, Cioffi F, Ptacek J, et al. Association between B-cell receptor responsiveness and disease progression in B-cell chronic lymphocytic leukemia: results from single cell network profiling studies. Haematologica. 2013;98(4):626\u201334.","journal-title":"Haematologica"},{"issue":"1","key":"2468_CR65","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1182\/blood-2015-11-681460","volume":"128","author":"NS Saba","year":"2016","unstructured":"Saba NS, Liu D, Herman SEM, Underbayev C, Tian X, Behrend D, et al. Pathogenic role of B-cell receptor signaling and canonical NF-\u03baB activation in mantle cell lymphoma. Blood. 2016;128(1):82\u201392.","journal-title":"Blood"},{"issue":"1","key":"2468_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-55728-9","volume":"14","author":"S Gambino","year":"2024","unstructured":"Gambino S, Quaglia FM, Galasso M, Cavallini C, Chignola R, Lovato O, et al. B-cell receptor signaling activity identifies patients with mantle cell lymphoma at higher risk of progression. Sci Rep. 2024;14(1):6595. https:\/\/doi.org\/10.1038\/s41598-024-55728-9.","journal-title":"Sci Rep"},{"issue":"6","key":"2468_CR67","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1182\/blood-2016-05-718494","volume":"129","author":"JH Myklebust","year":"2017","unstructured":"Myklebust JH, Brody J, Kohrt HE, Kolstad A, Czerwinski DK, W\u00e4lchli S, et al. Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling. Blood. 2017;129(6):759\u201370.","journal-title":"Blood"},{"key":"2468_CR68","doi-asserted-by":"crossref","unstructured":"Cheng S, Guo A, Lu P, Ma J, Coleman M, Wang YL. Functional characterization of BTK C481S mutation that confers ibrutinib resistance: Exploration of alternative kinase inhibitors. Leukemia. 2015 [cited 2023 Mar 24];29(4):895\u2013900. Available from: https:\/\/www.nature.com\/articles\/leu2014263","DOI":"10.1038\/leu.2014.263"},{"key":"2468_CR69","doi-asserted-by":"crossref","unstructured":"Cheng S, Ma J, Guo A, Lu P, Leonard JP, Coleman M, et al. BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity. Leukemia. 2013 [cited 2025 Sep 3];28(3):649\u201357. Available from: https:\/\/www.nature.com\/articles\/leu2013358","DOI":"10.1038\/leu.2013.358"},{"key":"2468_CR70","doi-asserted-by":"crossref","unstructured":"Dictor M, Ek S, Sundberg M, Warenholt J, Gy\u00f6rgy C, Sernbo S, et al. Strong lymphoid nuclear expression of SOX11 transcription factor defines lymphoblastic neoplasms, mantle cell lymphoma and Burkitt\u2019s lymphoma. Haematologica. 2009 [cited 2024 Apr 9];94(11):1563\u20138. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/19880779\/","DOI":"10.3324\/haematol.2009.008474"},{"key":"2468_CR71","doi-asserted-by":"crossref","unstructured":"Schmitz R, Ceribelli M, Pittaluga S, Wright G, Staudt LM. Oncogenic Mechanisms in Burkitt Lymphoma. 2014 [cited 2025 Jun 9]; Available from: http:\/\/perspectivesinmedicine.cshlp.org\/","DOI":"10.1101\/cshperspect.a014282"},{"key":"2468_CR72","doi-asserted-by":"crossref","unstructured":"Schmitz R, Young RM, Ceribelli M, Jhavar S, Xiao W, Zhang M, et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature 2012 490:7418. 2012 [cited 2025 Jun 9];490(7418):116\u201320. Available from: https:\/\/www.nature.com\/articles\/nature11378","DOI":"10.1038\/nature11378"},{"key":"2468_CR73","doi-asserted-by":"crossref","unstructured":"Rudelius M, Pittaluga S, Nishizuka S, Pham THT, Fend F, Jaffe ES, et al. Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma. Blood]. 2006 [cited 2023 Feb 15];108(5):1668\u201376. Available from: https:\/\/ashpublications.org\/blood\/article\/108\/5\/1668\/132627\/Constitutive-activation-of-Akt-contributes-to-the","DOI":"10.1182\/blood-2006-04-015586"},{"key":"2468_CR74","doi-asserted-by":"crossref","unstructured":"Saleh K, Cheminant M, Chiron D, Burroni B, Ribrag V, Sarkozy C. Tumor Microenvironment and Immunotherapy-Based Approaches in Mantle Cell Lymphoma. Cancers 2022, Vol 14, Page 3229]. 2022 [cited 2025 Jun 4];14(13):3229. Available from: https:\/\/www.mdpi.com\/2072-6694\/14\/13\/3229\/htm","DOI":"10.3390\/cancers14133229"},{"key":"2468_CR75","doi-asserted-by":"crossref","unstructured":"Palomero J, Vegliante MC, Rodr\u00edguez ML, Eguileor \u00c1, Castellano G, Planas-Rigol E, et al. SOX11 promotes tumor angiogenesis through transcriptional regulation of PDGFA in mantle cell lymphoma. Blood. 2014 [cited 2022 Aug 8];124(14):2235\u201347. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/25092176\/","DOI":"10.1182\/blood-2014-04-569566"},{"issue":"4","key":"2468_CR76","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1182\/blood-2017-04-776740","volume":"130","author":"P Balsas","year":"2017","unstructured":"Balsas P, Palomero J, Eguileor \u00c1, Rodr\u00edguez ML, Vegliante MC, Planas-Rigol E, et al. SOX11 promotes tumor protective microenvironment interactions through CXCR4 and FAK regulation in mantle cell lymphoma. Blood. 2017;130(4):501\u201313.","journal-title":"Blood"},{"key":"2468_CR77","doi-asserted-by":"crossref","unstructured":"Balsas P, Veloza L, Clot G, Sureda-G\u00f3mez M, Rodr\u00edguez ML, Masaoutis C, et al. SOX11, CD70, and Treg cells configure the tumor immune microenvironment of aggressive mantle cell lymphoma. Blood. 2021 [cited 2025 Jun 6];138(22):2202\u201315. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0006497121012969","DOI":"10.1182\/blood.2020010527"},{"key":"2468_CR78","doi-asserted-by":"publisher","unstructured":"Dutta RP, Lee HH, Leshchenko V V., Shukla RP, Yan F, Liu Y, et al. SOX11 Modulates BCR Signaling Through the PAX5\/CD19 Axis for Therapeutic Targeting in BTK Resistant Mantle Cell Lymphoma. Blood Adv. 2025 [cited 2025 Sep 1]; Available from: https:\/\/doi.org\/10.1182\/bloodadvances.2025016801","DOI":"10.1182\/bloodadvances.2025016801"},{"key":"2468_CR79","doi-asserted-by":"crossref","unstructured":"Jatiani SS, Christie S, Leshchenko V V., Jain R, Kapoor A, Bisignano P, et al. SOX11 inhibitors are cytotoxic in mantle cell lymphoma. Clin Cancer Res. 2021 [cited 2022 Aug 1];27(16):4652\u201363. Available from: \/pmc\/articles\/PMC8364871\/","DOI":"10.1158\/1078-0432.CCR-20-5039"},{"key":"2468_CR80","doi-asserted-by":"crossref","unstructured":"Jain P, Nomie K, Kotlov N, Segodin VI, Hill H, Ok CY, et al. Immune-depleted tumor microenvironment is associated with poor outcomes and BTK inhibitor resistance in mantle cell lymphoma. Blood Cancer Journal 2023 13:1. 2023 [cited 2025 Jan 14];13(1):1\u20135. Available from: https:\/\/www.nature.com\/articles\/s41408-023-00927-2","DOI":"10.1038\/s41408-023-00927-2"},{"key":"2468_CR81","doi-asserted-by":"publisher","unstructured":"Ruan J, Martin P, Shah B, Schuster SJ, Smith SM, Furman RR, et al. Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma. New Engl J Med. 2015 [cited 2025 Jun 6];373(19):1835\u201344. Available from: https:\/\/www.nejm.org\/doi\/pdf\/https:\/\/doi.org\/10.1056\/NEJMoa1505237","DOI":"10.1056\/NEJMoa1505237"},{"key":"2468_CR82","doi-asserted-by":"crossref","unstructured":"Roider T, Baertsch MA, Fitzgerald D, V\u00f6hringer H, Brinkmann BJ, Czernilofsky F, et al. Multimodal and spatially resolved profiling identifies distinct patterns of T cell infiltration in nodal B cell lymphoma entities. Nature Cell Biology 2024 26:3. 2024 [cited 2025 Jun 6];26(3):478\u201389. Available from: https:\/\/www.nature.com\/articles\/s41556-024-01358-2","DOI":"10.1038\/s41556-024-01358-2"},{"key":"2468_CR83","doi-asserted-by":"crossref","unstructured":"Siddiqui I, Schaeuble K, Chennupati V, Fuertes Marraco SA, Calderon-Copete S, Pais Ferreira D, et al. Intratumoral Tcf1+PD-1+CD8+ T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy. Immunity. 2019 [cited 2025 Jun 6];50(1):195\u2013211.e10. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1074761318305697?via%3Dihub","DOI":"10.1016\/j.immuni.2018.12.021"},{"key":"2468_CR84","doi-asserted-by":"crossref","unstructured":"Miller BC, Sen DR, Al Abosy R, Bi K, Virkud Y V., LaFleur MW, et al. Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade. Nature Immunology 2019 20:3. 2019 [cited 2025 Jun 6];20(3):326\u201336. Available from: https:\/\/www.nature.com\/articles\/s41590-019-0312-6","DOI":"10.1038\/s41590-019-0312-6"},{"key":"2468_CR85","doi-asserted-by":"crossref","unstructured":"Armand P, Janssens A, Gritti G, Radford J, Timmerman J, Pinto A, et al. Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed\/refractory follicular lymphoma. Blood. 2021 [cited 2025 Jun 6];137(5):637\u201345. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/32870269\/","DOI":"10.1182\/blood.2019004753"},{"key":"2468_CR86","doi-asserted-by":"crossref","unstructured":"Zhang T, Ren T, Song Z, Zhao J, Jiao L, Zhang Z, et al. Genetic mutations of TIM-3 ligand and exhausted TIM-3+ CD8+ T cells and survival in diffuse large B cell lymphoma. J Immunol Res. 2020 [cited 2025 Jun 6];2020. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/33178839\/","DOI":"10.1155\/2020\/6968595"},{"key":"2468_CR87","doi-asserted-by":"crossref","unstructured":"Yang ZZ, Kim HJ, Villasboas JC, Chen YP, Price-Troska TP, Jalali S, et al. Expression of LAG-3 defines exhaustion of intratumoral PD-1+ T cells and correlates with poor outcome in follicular lymphoma. Oncotarget. 2017 [cited 2025 Jun 6];8(37):61425\u201339. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/28977875\/","DOI":"10.18632\/oncotarget.18251"},{"issue":"3","key":"2468_CR88","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1158\/2326-6066.CIR-18-0351","volume":"7","author":"SE Josefsson","year":"2019","unstructured":"Josefsson SE, Beiske K, Blaker YN, Kimby E, Smeland EB, Levy R, et al. TIGIT and PD-1 mark intratumoral T cells with reduced effector function in B-cell non-Hodgkin lymphoma. Cancer Immunol Res. 2019;7(3):355\u201362.","journal-title":"Cancer Immunol Res"},{"key":"2468_CR89","doi-asserted-by":"crossref","unstructured":"Qualls D, Kumar A, Epstein-Peterson ZD. Targeting the Immune Microenvironment in Mantle Cell Lymphoma: Implications for Current and Emerging Therapies. Leuk Lymphoma. 2022 [cited 2025 Jun 6];63(11):2515. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9741766\/","DOI":"10.1080\/10428194.2022.2086244"},{"issue":"1","key":"2468_CR90","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1182\/blood-2022-163381","volume":"140","author":"F Araujo-Ayala","year":"2022","unstructured":"Araujo-Ayala F, Doba\u00f1o-L\u00f3pez C, Valero JG, Nadeu F, Gava F, Faria C, et al. Combination of ibrutinib and nivolumab overcomes ibrutinib resistance in a novel patient-derived mantle cell lymphoma 3D model. Blood. 2022;140(1):1323\u20134. https:\/\/doi.org\/10.1182\/blood-2022-163381.","journal-title":"Blood"},{"issue":"7","key":"2468_CR91","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1182\/blood.2023022351","volume":"145","author":"C Sarkozy","year":"2025","unstructured":"Sarkozy C, Tessoulin B, Chiron D. Unraveling MCL biology to understand resistance and identify vulnerabilities. Blood. 2025;145(7):696\u2013707. https:\/\/doi.org\/10.1182\/blood.2023022351.","journal-title":"Blood"},{"key":"2468_CR92","doi-asserted-by":"crossref","unstructured":"Nylund P, Nikkarinen A, Ek S, Glimelius I. Empowering macrophages: the cancer fighters within the tumour microenvironment in mantle cell lymphoma. Vol. 15, Frontiers in Immunology. Frontiers Media SA; 2024. p. 1373269","DOI":"10.3389\/fimmu.2024.1373269"},{"key":"2468_CR93","doi-asserted-by":"crossref","unstructured":"Nikkarinen A, Lokhande L, Amini RM, Jerkeman M, Porwit A, Molin D, et al. Soluble CD163 predicts outcome in both chemoimmunotherapy and targeted therapy\u2013treated mantle cell lymphoma. Blood Adv. 2023 [cited 2025 Jun 6];7(18):5304. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10506048\/","DOI":"10.1182\/bloodadvances.2023010052"},{"key":"2468_CR94","doi-asserted-by":"crossref","unstructured":"de Matos Rodrigues J, Lokhande L, Olsson LM, Hassan M, Johansson A, Jansk\u00e1 A, et al. CD163+ macrophages in mantle cell lymphoma induce activation of prosurvival pathways and immune suppression. Blood Adv. 2024 [cited 2025 Jun 6];8(16):4370\u201385. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/38959399\/","DOI":"10.1182\/bloodadvances.2023012039"},{"key":"2468_CR95","doi-asserted-by":"crossref","unstructured":"Decombis S, Papin A, Bellanger C, Sortais C, Dousset C, Le Bris Y, et al. The IL32\/BAFF axis supports prosurvival dialogs in the lymphoma ecosystem and is disrupted by NIK inhibition. Haematologica. 2022 [cited 2023 Mar 3];107(12):2905\u201317. Available from: https:\/\/haematologica.org\/article\/view\/haematol.2021.279800","DOI":"10.3324\/haematol.2021.279800"},{"issue":"10","key":"2468_CR96","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.1038\/s41375-019-0463-3","volume":"33","author":"A Papin","year":"2019","unstructured":"Papin A, Tessoulin B, Bellanger C, Moreau A, Le Bris Y, Maisonneuve H, et al. CSF1R and BTK inhibitions as novel strategies to disrupt the dialog between mantle cell lymphoma and macrophages. Leukemia. 2019;33(10):2442\u201353.","journal-title":"Leukemia"},{"issue":"14","key":"2468_CR97","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1182\/bloodadvances.2020003871","volume":"5","author":"K Le","year":"2021","unstructured":"Le K, Sun J, Khawaja H, Shibata M, Maggirwar SB, Smith MR, et al. Mantle cell lymphoma polarizes tumor-associated macrophages into M2-like macrophages, which in turn promote tumorigenesis. Blood Adv. 2021;5(14):2863\u201378. https:\/\/doi.org\/10.1182\/bloodadvances.2020003871.","journal-title":"Blood Adv"},{"key":"2468_CR98","doi-asserted-by":"publisher","unstructured":"Aprile von Hohenstaufen K, Conconi A, de Campos CP, Franceschetti S, Bertoni F, Margiotta Casaluci G, et al. Prognostic impact of monocyte count at presentation in mantle cell lymphoma. Br J Haematol. 2013 [cited 2025 Jul 24];162(4):465\u201373. Available from: \/doi\/pdf\/https:\/\/doi.org\/10.1111\/bjh.12409","DOI":"10.1111\/bjh.12409"},{"key":"2468_CR99","doi-asserted-by":"publisher","unstructured":"Duminuco A, Romano A, Ferrarini I, Santuccio G, Chiarenza A, Figuera A, et al. Monocyte-to-platelets ratio (MPR) at diagnosis is associated with inferior progression-free survival in patients with mantle cell lymphoma: a multi-center real-life survey. Ann Hematol. 2024 [cited 2025 Jun 10];103(8):3043\u201352. Available from: https:\/\/link.springer.com\/article\/https:\/\/doi.org\/10.1007\/s00277-024-05752-6","DOI":"10.1007\/s00277-024-05752-6"},{"key":"2468_CR100","doi-asserted-by":"crossref","unstructured":"Nguyen PH, Niesen E, Hallek M. New roles for B cell receptor associated kinases: when the B cell is not the target. Leukemia 2019 33:3. 2019 [cited 2025 Jun 9];33(3):576\u201387. Available from: https:\/\/www.nature.com\/articles\/s41375-018-0366-8","DOI":"10.1038\/s41375-018-0366-8"},{"issue":"1","key":"2468_CR101","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/imr.12792","volume":"291","author":"RM Young","year":"2019","unstructured":"Young RM, Phelan JD, Wilson WH, Staudt LM. Pathogenic b-cell receptor signaling in lymphoid malignancies: new insights to improve treatment. Immunol Rev. 2019;291(1):190\u2013213.","journal-title":"Immunol Rev"},{"issue":"6","key":"2468_CR102","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1182\/blood-2015-06-654111","volume":"127","author":"M Szydlowski","year":"2016","unstructured":"Szydlowski M, Kiliszek P, Sewastianik T, Jablonska E, Bialopiotrowicz E, Gorniak P, et al. FOXO1 activation is an effector of SYK and AKT inhibition in tonic BCR signal-dependent diffuse large B-cell lymphomas. Blood. 2016;127(6):739\u201348. https:\/\/doi.org\/10.1182\/blood-2015-06-654111.","journal-title":"Blood"},{"issue":"13","key":"2468_CR103","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1182\/blood-2009-08-236471","volume":"115","author":"JW Friedberg","year":"2010","unstructured":"Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, LaCasce A, et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 2010;115(13):2578\u201385. https:\/\/doi.org\/10.1182\/blood-2009-08-236471.","journal-title":"Blood"},{"key":"2468_CR104","doi-asserted-by":"crossref","unstructured":"Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, et al. Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia. New Engl J Med. 2013 [cited 2025 Jun 9];369(1):32\u201342. Available from: https:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMoa1215637","DOI":"10.1056\/NEJMoa1215637"},{"key":"2468_CR105","doi-asserted-by":"crossref","unstructured":"Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ, et al. PI3K\u03b4 Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma. New Engl J Med. 2014 [cited 2025 Jun 9];370(11):1008\u201318. Available from: https:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMoa1314583","DOI":"10.1056\/NEJMoa1314583"},{"key":"2468_CR106","doi-asserted-by":"crossref","unstructured":"Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, et al. Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia. New Engl J Med. 2014 [cited 2025 Feb 3];370(11):997\u20131007. Available from: https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa1315226","DOI":"10.1056\/NEJMoa1315226"},{"key":"2468_CR107","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2025.101273","volume":"20","author":"X Liu","year":"2025","unstructured":"Liu X, Lin Y, Zhuang Q, Deng H, Liu A, Sun J. BTK inhibitors resistance in B cell malignancies: mechanisms and potential therapeutic strategies. Blood Rev. 2025;20:101273.","journal-title":"Blood Rev"},{"key":"2468_CR108","doi-asserted-by":"crossref","unstructured":"Burger JA, Wiestner A. Targeting B cell receptor signalling in cancer: preclinical and clinical advances. Nat Rev Cancer. 2018 [cited 2023 Jan 30];18(3):148\u201367. Available from: https:\/\/www.nature.com\/articles\/nrc.2017.121","DOI":"10.1038\/nrc.2017.121"},{"key":"2468_CR109","doi-asserted-by":"crossref","unstructured":"Pan Z, Scheerens H, Li SJ, Schultz BE, Sprengeler PA, Burrill LC, et al. Discovery of selective irreversible inhibitors for Bruton\u2019s tyrosine kinase. ChemMedChem. 2007 [cited 2025 Jan 29];2(1):58\u201361. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/17154430\/","DOI":"10.1002\/cmdc.200600221"},{"key":"2468_CR110","doi-asserted-by":"crossref","unstructured":"Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, et al. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. New Engl J Med. 2015 [cited 2025 Jun 9];373(25):2425\u201337. Available from: https:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMoa1509388","DOI":"10.1056\/NEJMoa1509388"},{"key":"2468_CR111","doi-asserted-by":"crossref","unstructured":"Shanafelt TD, Wang X V., Kay NE, Hanson CA, O\u2019Brien S, Barrientos J, et al. Ibrutinib\u2013Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia. New Engl J Med]. 2019 [cited 2025 Jun 9];381(5):432\u201343. Available from: https:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMoa1817073","DOI":"10.1056\/NEJMoa1817073"},{"key":"2468_CR112","doi-asserted-by":"crossref","unstructured":"Treon SP, Tripsas CK, Meid K, Warren D, Varma G, Green R, et al. Ibrutinib in Previously Treated Waldenstr\u00f6m\u2019s Macroglobulinemia. New Engl J Med. 2015 [cited 2025 Jun 9];372(15):1430\u201340. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/25853747\/","DOI":"10.1056\/NEJMoa1501548"},{"key":"2468_CR113","doi-asserted-by":"publisher","unstructured":"Tam CS, Investigators for the A, Opat S, Investigators for the A, D\u2019Sa S, Investigators for the A, et al. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstr\u00f6m macroglobulinemia: the ASPEN study. Blood. 2020 [cited 2025 Jun 9];136(18):2038\u201350. Available from: https:\/\/doi.org\/10.1182\/blood.2020006844","DOI":"10.1182\/blood.2020006844"},{"key":"2468_CR114","doi-asserted-by":"crossref","unstructured":"Treon SP, Meid K, Gustine J, Yang G, Xu L, Liu X, et al. Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients with Waldenstr\u00f6m Macroglobulinemia. J Clin Oncol. 2021 [cited 2025 Jun 9];39(6):565\u201375. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/32931398\/","DOI":"10.1200\/JCO.20.00555"},{"issue":"22","key":"2468_CR115","doi-asserted-by":"publisher","first-page":"5773","DOI":"10.1182\/bloodadvances.2020003121","volume":"4","author":"A Noy","year":"2020","unstructured":"Noy A, de Vos S, Coleman M, Martin P, Flowers CR, Thieblemont C, et al. Durable ibrutinib responses in relapsed\/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis. Blood Adv. 2020;4(22):5773\u201384. https:\/\/doi.org\/10.1182\/bloodadvances.2020003121.","journal-title":"Blood Adv"},{"key":"2468_CR116","doi-asserted-by":"crossref","unstructured":"Woyach JA, Barr PM, Kipps TJ, Barrientos JC, Ahn IE, Ghia P, et al. Characteristics and Clinical Outcomes of Patients with Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma Receiving Ibrutinib for \u22655 Years in the RESONATE-2 Study. Cancers (Basel). 2023 [cited 2025 Jun 9];15(2):507. Available from: https:\/\/www.mdpi.com\/2072-6694\/15\/2\/507\/htm","DOI":"10.3390\/cancers15020507"},{"key":"2468_CR117","doi-asserted-by":"crossref","unstructured":"Mato AR, Roeker LE, Allan JN, Pagel JM, Brander DM, Hill BT, et al. Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial. Am J Hematol. 2018 [cited 2025 Jun 9];93(11):1394. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC7552812\/","DOI":"10.1002\/ajh.25261"},{"key":"2468_CR118","doi-asserted-by":"crossref","unstructured":"Zhao X, Lwin T, Silva A, Shah B, Tao J, Fang B, et al. Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma. Nat Commun. 2017 [cited 2023 Mar 24];8. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/28416797\/","DOI":"10.1038\/ncomms14920"},{"issue":"Supplement_1","key":"2468_CR119","doi-asserted-by":"publisher","first-page":"2762","DOI":"10.1182\/blood-2019-130512","volume":"134","author":"K Nomie","year":"2019","unstructured":"Nomie K, Kotlov N, Svekolkin V, Bagaev A, Cai Q, Falahat J, et al. Tumor microenvironment molecular signatures that define therapeutic resistance in mantle cell lymphoma. Blood. 2019;134(Supplement_1):2762\u20132762. https:\/\/doi.org\/10.1182\/blood-2019-130512.","journal-title":"Blood"},{"issue":"14","key":"2468_CR120","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1182\/blood-2013-02-482125","volume":"122","author":"BY Chang","year":"2013","unstructured":"Chang BY, Francesco M, De Rooij MFM, Magadala P, Steggerda SM, Huang MM, et al. Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients. Blood. 2013;122(14):2412\u201324. https:\/\/doi.org\/10.1182\/blood-2013-02-482125.","journal-title":"Blood"},{"issue":"15","key":"2468_CR121","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1182\/blood-2013-06-507947","volume":"122","author":"JA Dubovsky","year":"2013","unstructured":"Dubovsky JA, Beckwith KA, Natarajan G, Woyach JA, Jaglowski S, Zhong Y, et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood. 2013;122(15):2539\u201349. https:\/\/doi.org\/10.1182\/blood-2013-06-507947.","journal-title":"Blood"},{"issue":"24","key":"2468_CR122","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1182\/blood.2019852368","volume":"133","author":"TE Witzig","year":"2019","unstructured":"Witzig TE, Inwards D. Acalabrutinib for mantle cell lymphoma. Blood. 2019;133(24):2570\u20134.","journal-title":"Blood"},{"issue":"10121","key":"2468_CR123","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/S0140-6736(17)33108-2","volume":"391","author":"M Wang","year":"2018","unstructured":"Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith SD, et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Lancet. 2018;391(10121):659\u201367. https:\/\/doi.org\/10.1016\/S0140-6736(17)33108-2.","journal-title":"Lancet"},{"key":"2468_CR124","unstructured":"Le Gouill S, D\u0142ugosz-Danecka M, Rule S, Zinzani PL, Goy A, Smith SD, et al. Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed\/refractory mantle cell lymphoma, including those with poor prognostic factors. Haematologica. 2024 [cited 2025 Jun 9];109(1):343\u201350. Available from: https:\/\/haematologica.org\/article\/view\/haematol.2022.282469"},{"issue":"21","key":"2468_CR125","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.1182\/blood.2021014162","volume":"139","author":"Y Song","year":"2022","unstructured":"Song Y, Zhou K, Zou D, Zhou J, Hu J, Yang H, et al. Zanubrutinib in relapsed\/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study. Blood. 2022;139(21):3148\u201358. https:\/\/doi.org\/10.1182\/blood.2021014162.","journal-title":"Blood"},{"key":"2468_CR126","doi-asserted-by":"crossref","unstructured":"Song Y, Zhou K, Zou D, Zhou J, Hu J, Yang H, et al. Treatment of Patients with Relapsed or Refractory Mantle\u2013Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton\u2019s Tyrosine Kinase. Clin Cancer Res. 2020 [cited 2025 Jun 9];26(16):4216\u201324. Available from: \/clincancerres\/article\/26\/16\/4216\/82762\/Treatment-of-Patients-with-Relapsed-or-Refractory","DOI":"10.1158\/1078-0432.CCR-19-3703"},{"key":"2468_CR127","doi-asserted-by":"crossref","unstructured":"Shadman M, Flinn IW, Levy MY, Porter RF, Burke JM, Zafar SF, et al. Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study. Lancet Haematol. 2023 [cited 2025 Jun 9];10(1):e35\u201345. Available from: https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S2352302622003209?via%3Dihub","DOI":"10.1016\/S2352-3026(22)00320-9"},{"key":"2468_CR128","doi-asserted-by":"publisher","unstructured":"Shadman M, Burke JM, Cultrera J, Yimer HA, Zafar SF, Misleh J, et al. Zanubrutinib is well tolerated and effective in CLL\/SLL patients intolerant of ibrutinib\/acalabrutinib: Updated results. Blood Adv. 2025 [cited 2025 Jun 9]; Available from: https:\/\/doi.org\/10.1182\/bloodadvances.2024015493","DOI":"10.1182\/bloodadvances.2024015493"},{"key":"2468_CR129","doi-asserted-by":"crossref","unstructured":"Zinzani PL, Mayer J, Flowers CR, Bijou F, De Oliveira AC, Song Y, et al. ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients with Relapsed or Refractory Follicular Lymphoma. Journal of Clinical Oncology [Internet]. 2023 [cited 2025 Sep 1];41(33):5107\u201317. Available from: https:\/\/ascopubs.org\/doi\/pdf\/10.1200\/JCO.23.00775","DOI":"10.1200\/JCO.23.00775"},{"key":"2468_CR130","doi-asserted-by":"crossref","unstructured":"Wang ML, Jurczak W, Zinzani PL, Eyre TA, Cheah CY, Ujjani CS, et al. Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma. J Clin Oncol. 2023 [cited 2025 Jun 9];41(24):3988\u201397. Available from: https:\/\/ascopubs.org\/doi\/pdf\/10.1200\/JCO.23.00562","DOI":"10.1200\/JCO.23.00562"},{"issue":"Supplement 1","key":"2468_CR131","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1182\/blood-2023-181627","volume":"142","author":"JB Cohen","year":"2023","unstructured":"Cohen JB, Shah NN, Jurczak W, Zinzani PL, Cheah CY, Eyre TA, et al. Pirtobrutinib in relapsed\/refractory (R\/R) mantle cell lymphoma (MCL) patients with prior cBTKi: safety and efficacy including high-risk subgroup analyses from the phase 1\/2 BRUIN study. Blood. 2023;142(Supplement 1):981\u2013981. https:\/\/doi.org\/10.1182\/blood-2023-181627.","journal-title":"Blood"},{"key":"2468_CR132","doi-asserted-by":"crossref","unstructured":"Kong C, Wu M, Lu Q, Ke B, Xie J, Li A. PI3K\/AKT confers intrinsic and acquired resistance to pirtobrutinib in chronic lymphocytic leukemia. Leuk Res. 2024 [cited 2025 Jun 10];144:107548. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0145212624001140?via%3Dihub","DOI":"10.1016\/j.leukres.2024.107548"},{"key":"2468_CR133","doi-asserted-by":"crossref","unstructured":"Searle E, Forconi F, Linton K, Danilov A, McKay P, Lewis D, et al. Initial Findings from a First-in-Human Phase 1a\/b Trial of NX-5948, a Selective Bruton\u2019s Tyrosine Kinase (BTK) Degrader, in Patients with Relapsed\/Refractory B Cell Malignancies. Blood. 2023 [cited 2025 Jun 9];142(Supplement 1):4473. Available from: https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0006497123110743","DOI":"10.1182\/blood-2023-179508"},{"key":"2468_CR134","doi-asserted-by":"crossref","unstructured":"Salvaris RT, Brennan J, Lewis KL. BTK Is the Target That Keeps on Giving: A Review of BTK-Degrader Drug Development, Clinical Data, and Future Directions in CLL. Cancers 2025, Vol 17, Page 557. 2025 [cited 2025 Jun 9];17(3):557. Available from: https:\/\/www.mdpi.com\/2072-6694\/17\/3\/557\/htm","DOI":"10.3390\/cancers17030557"},{"issue":"4","key":"2468_CR135","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1111\/bjh.16416","volume":"189","author":"R McCulloch","year":"2020","unstructured":"McCulloch R, Visco C, Eyre TA, Frewin R, Phillips N, Tucker DL, et al. Efficacy of R-BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy. Br J Haematol. 2020;189(4):684\u20138.","journal-title":"Br J Haematol"},{"issue":"8","key":"2468_CR136","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.4049\/jimmunol.1801327","volume":"203","author":"Q Zhang","year":"2019","unstructured":"Zhang Q, Wang HY, Liu X, Nunez-Cruz S, Jillab M, Melnikov O, et al. Cutting edge: ROR1\/CD19 receptor complex promotes growth of mantle cell lymphoma cells independently of the B cell receptor\u2013BTK signaling pathway. J Immunol. 2019;203(8):2043\u20138.","journal-title":"J Immunol"},{"key":"2468_CR137","doi-asserted-by":"publisher","unstructured":"Jain P, Kanagal-Shamanna R, Zhang S, Ahmed M, Ghorab A, Zhang L, et al. Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib. Br J Haematol. 2018 [cited 2025 Jun 9];183(4):578\u201387. Available from: https:\/\/doi.org\/10.1111\/bjh.15567","DOI":"10.1111\/bjh.15567"},{"key":"2468_CR138","doi-asserted-by":"publisher","unstructured":"Nakhoda S, Vistarop A, Wang YL. Resistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non-Hodgkin lymphoma. Br J Haematol. 2023 [cited 2025 Sep 1];200(2):137\u201349. Available from: https:\/\/doi.org\/10.1111\/bjh.18418","DOI":"10.1111\/bjh.18418"},{"key":"2468_CR139","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.3389\/fimmu.2021.689472","volume":"12","author":"CIE Smith","year":"2021","unstructured":"Smith CIE, Burger JA, Frontiers Media S.A. Resistance mutations to BTK inhibitors originate from the NF-\u03baB but not from the PI3K-RAS-MAPK arm of the B cell receptor signaling pathway. Front Immunol. 2021;12:1908.","journal-title":"Front Immunol"},{"key":"2468_CR140","doi-asserted-by":"crossref","unstructured":"Woyach J, Huang Y, Rogers K, Bhat SA, Grever MR, Lozanski A, et al. Resistance to Acalabrutinib in CLL Is Mediated Primarily By BTK Mutations. Blood. 2019;134(Supplement_1):504.","DOI":"10.1182\/blood-2019-127674"},{"key":"2468_CR141","doi-asserted-by":"crossref","unstructured":"Polcik L, Dannewitz Prosseda S, Pozzo F, Zucchetto A, Gattei V, Hartmann TN. Integrin Signaling Shaping BTK-Inhibitor Resistance. Cells 2022, Vol 11, Page 2235. 2022 [cited 2025 Jul 21];11(14):2235. Available from: https:\/\/www.mdpi.com\/2073-4409\/11\/14\/2235\/htm","DOI":"10.3390\/cells11142235"},{"key":"2468_CR142","doi-asserted-by":"crossref","unstructured":"Guan J, Huang D, Yakimchuk K, Okret S. p110a inhibition overcomes stromal cell\u2013mediated ibrutinib resistance in mantle cell lymphoma. Mol Cancer Ther. 2018 [cited 2025 Apr 14];17(5):1090\u2013100. Available from: \/mct\/article\/17\/5\/1090\/92400\/p110-Inhibition-Overcomes-Stromal-Cell-Mediated","DOI":"10.1158\/1535-7163.MCT-17-0784"},{"key":"2468_CR143","doi-asserted-by":"crossref","unstructured":"Yamaki H, Nakajima M, Shimotohno KW, Tanaka N. Molecular basis for the actions of Hsp90 inhibitors and cancer therapy. The Journal of Antibiotics 2011 64:9. 2011 [cited 2025 Jun 9];64(9):635\u201344. Available from: https:\/\/www.nature.com\/articles\/ja201160","DOI":"10.1038\/ja.2011.60"},{"key":"2468_CR144","doi-asserted-by":"crossref","unstructured":"Lee J, Zhang LL, Wu W, Guo H, Li Y, Sukhanova M, et al. Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma. Blood Adv. 2018 [cited 2025 Jun 9];2(16):2039\u201351. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2473952920308818","DOI":"10.1182\/bloodadvances.2018026344"},{"key":"2468_CR145","doi-asserted-by":"publisher","unstructured":"Jiang VC, Liu Y, Lian J, Huang S, Jordan A, Cai Q, et al. Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma. J Clin Invest. 2025 [cited 2025 Jun 9];133(3). Available from: https:\/\/doi.org\/10.1172\/JCI165694","DOI":"10.1172\/JCI165694"},{"key":"2468_CR146","doi-asserted-by":"crossref","unstructured":"Vallabhapurapu S, Matsuzawa A, Zhang WZ, Tseng PH, Keats JJ, Wang H, et al. Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-\u03baB signaling. Nat Immunol. 2008 [cited 2025 Jun 9];9(12):1364\u201370. Available from: https:\/\/www.nature.com\/articles\/ni.1678","DOI":"10.1038\/ni.1678"},{"key":"2468_CR147","doi-asserted-by":"crossref","unstructured":"Azmi AS, Uddin MH, Mohammad RM. The nuclear export protein XPO1 \u2014 from biology to targeted therapy. Nature Reviews Clinical Oncology 2020 18:3. 2020 [cited 2025 Jun 9];18(3):152\u201369. Available from: https:\/\/www.nature.com\/articles\/s41571-020-00442-4","DOI":"10.1038\/s41571-020-00442-4"},{"key":"2468_CR148","doi-asserted-by":"crossref","unstructured":"Zhang Y, Lu P, Jin S, Zhang J, Zhou Y. USP14 promotes the malignant progression and ibrutinib resistance of mantle cell lymphoma by stabilizing XPO1. Int J Med Sci. 2023 [cited 2025 Jun 9];20(5):616\u201326. Available from: https:\/\/www.medsci.org:\/\/creativecommons.org\/licenses\/by\/4.0\/","DOI":"10.7150\/ijms.80467"},{"key":"2468_CR149","doi-asserted-by":"crossref","unstructured":"Ming M, Wu W, Xie B, Sukhanova M, Wang W, Kadri S, et al. XPO1 Inhibitor Selinexor Overcomes Intrinsic Ibrutinib Resistance in Mantle Cell Lymphoma via Nuclear Retention of I\u03baB. Mol Cancer Ther. 2018 [cited 2025 Sep 1];17(12):2564\u201374. Available from: \/mct\/article\/17\/12\/2564\/92506\/XPO1-Inhibitor-Selinexor-Overcomes-Intrinsic","DOI":"10.1158\/1535-7163.MCT-17-0789-ATR"},{"key":"2468_CR150","doi-asserted-by":"crossref","unstructured":"Moyo TK, Wilson CS, Moore DJ, Eischen CM. Myc enhances B-cell receptor signaling in precancerous B cells and confers resistance to Btk inhibition. Oncogene 2017 36:32. 2017 [cited 2025 Apr 14];36(32):4653\u201361. Available from: https:\/\/www.nature.com\/articles\/onc201795","DOI":"10.1038\/onc.2017.95"},{"key":"2468_CR151","doi-asserted-by":"crossref","unstructured":"Li L, Nie L, Jordan A, Cai Q, Liu Y, Li Y, et al. Targeting glutaminase is therapeutically effective in ibrutinib-resistant mantle cell lymphoma. Haematologica. 2023 [cited 2025 Jun 10];108(6):1616\u201327. Available from: https:\/\/www.sciencedirect.com\/org\/science\/article\/pii\/S1592872123001910","DOI":"10.3324\/haematol.2022.281538"},{"key":"2468_CR152","doi-asserted-by":"crossref","unstructured":"Fruman DA, Rommel C. PI3K and cancer: lessons, challenges and opportunities. Nature Reviews Drug Discovery 2014 13:2. 2014 [cited 2025 Jun 10];13(2):140\u201356. Available from: https:\/\/www.nature.com\/articles\/nrd4204","DOI":"10.1038\/nrd4204"},{"key":"2468_CR153","doi-asserted-by":"crossref","unstructured":"He Y, Sun MM, Zhang GG, Yang J, Chen KS, Xu WW, et al. Targeting PI3K\/Akt signal transduction for cancer therapy. Signal Transduction and Targeted Therapy 2021 6:1. 2021 [cited 2025 Jun 10];6(1):1\u201317. Available from: https:\/\/www.nature.com\/articles\/s41392-021-00828-5","DOI":"10.1038\/s41392-021-00828-5"},{"key":"2468_CR154","doi-asserted-by":"crossref","unstructured":"Yang J, Nie J, Ma X, Wei Y, Peng Y, Wei X. Targeting PI3K in cancer: mechanisms and advances in clinical trials. Molecular Cancer 2019 18:1. 2019 [cited 2025 Jun 10];18(1):1\u201328. Available from: https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/s12943-019-0954-x","DOI":"10.1186\/s12943-019-0954-x"},{"issue":"13","key":"2468_CR155","doi-asserted-by":"publisher","first-page":"3603","DOI":"10.1182\/blood-2011-05-352492","volume":"118","author":"J Hoellenriegel","year":"2011","unstructured":"Hoellenriegel J, Meadows SA, Sivina M, Wierda WG, Kantarjian H, Keating MJ, et al. The phosphoinositide 3\u2032-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood. 2011;118(13):3603\u201312. https:\/\/doi.org\/10.1182\/blood-2011-05-352492.","journal-title":"Blood"},{"issue":"2","key":"2468_CR156","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1182\/blood-2010-03-275305","volume":"117","author":"BJ Lannutti","year":"2011","unstructured":"Lannutti BJ, Meadows SA, Herman SEM, Kashishian A, Steiner B, Johnson AJ, et al. CAL-101, a p110\u03b4 selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood. 2011;117(2):591\u20134. https:\/\/doi.org\/10.1182\/blood-2010-03-275305.","journal-title":"Blood"},{"key":"2468_CR157","doi-asserted-by":"crossref","unstructured":"Brana I, Siu LL. Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment. BMC Med. 2012 [cited 2025 Feb 3];10(1):1\u201315. Available from: https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/1741-7015-10-161","DOI":"10.1186\/1741-7015-10-161"},{"issue":"22","key":"2468_CR158","doi-asserted-by":"publisher","first-page":"3390","DOI":"10.1182\/blood-2013-11-535047","volume":"123","author":"JR Brown","year":"2014","unstructured":"Brown JR, Byrd JC, Coutre SE, Benson DM, Flinn IW, Wagner-Johnston ND, et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110\u03b4, for relapsed\/refractory chronic lymphocytic leukemia. Blood. 2014;123(22):3390\u20137. https:\/\/doi.org\/10.1182\/blood-2013-11-535047.","journal-title":"Blood"},{"key":"2468_CR159","doi-asserted-by":"crossref","unstructured":"Eichhorst B, Ghia P, Niemann CU, Kater AP, Gregor M, Hallek M, et al. ESMO Clinical Practice Guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia. Ann Oncol. 2024 [cited 2025 Jun 10];35(9):762\u20138. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0923753424007476?via%3Dihub","DOI":"10.1016\/j.annonc.2024.06.016"},{"issue":"22","key":"2468_CR160","doi-asserted-by":"publisher","first-page":"3398","DOI":"10.1182\/blood-2013-11-537555","volume":"123","author":"BS Kahl","year":"2014","unstructured":"Kahl BS, Spurgeon SE, Furman RR, Flinn IW, Coutre SE, Brown JR, et al. A phase 1 study of the PI3K\u03b4 inhibitor idelalisib in patients with relapsed\/refractory mantle cell lymphoma (MCL). Blood. 2014;123(22):3398\u2013405. https:\/\/doi.org\/10.1182\/blood-2013-11-537555.","journal-title":"Blood"},{"key":"2468_CR161","doi-asserted-by":"crossref","unstructured":"Till KJ, Abdullah M, Alnassfan T, Janet GZ, Marks T, Coma S, et al. Roles of PI3K\u03b3 and PI3K\u03b4 in mantle cell lymphoma proliferation and migration contributing to efficacy of the PI3K\u03b3\/\u03b4 inhibitor duvelisib. Scientific Reports 2023 13:1. 2023 [cited 2023 Apr 28];13(1):1\u201310. Available from: https:\/\/www.nature.com\/articles\/s41598-023-30148-3","DOI":"10.1038\/s41598-023-30148-3"},{"key":"2468_CR162","doi-asserted-by":"crossref","unstructured":"Zinzani PL, Trn\u011bn\u00fd M, Ribrag V, Zilioli VR, Walewski J, Christensen JH, et al. Parsaclisib, a PI3K\u03b4 inhibitor, in relapsed and refractory mantle cell lymphoma (CITADEL-205): a phase 2 study. EClinicalMedicine. 2023 [cited 2025 Jul 24];62:102131. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2589537023003085?via%3Dihub","DOI":"10.1016\/j.eclinm.2023.102131"}],"container-title":["Cell Communication and Signaling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-025-02468-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12964-025-02468-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-025-02468-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T15:24:22Z","timestamp":1762874662000},"score":1,"resource":{"primary":{"URL":"https:\/\/biosignaling.biomedcentral.com\/articles\/10.1186\/s12964-025-02468-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,11]]},"references-count":162,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2468"],"URL":"https:\/\/doi.org\/10.1186\/s12964-025-02468-6","relation":{},"ISSN":["1478-811X"],"issn-type":[{"value":"1478-811X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,11]]},"assertion":[{"value":"1 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"486"}}